A randomized study comparing rectally administered misoprostol after spinal anesthesia versus intramuscular oxytocin for prevention of postpartum hemorrhage in caesarean section
Keywords:
Postpartum Hemorrhage, Misoprostol, OxytocinAbstract
Background: Post-Partum Hemorrhage (PPH) is the commonest cause of maternal death worldwide. Studies suggest that the use of Misoprostol may be beneficial in clinical settings where oxytocin is unavailable. However studies are limited that show its use in prevention of PPH in high risk pregnancy involving elective caesarean section. Therefore our aim of study is to compare the effectiveness of rectal misoprostol with intramuscular oxytocin in the prevention of postpartum hemorrhage in cesarean sections.
Methods: In a double-blind randomized controlled trial, 200 pregnant women who had cesarean sections were assigned into two groups: to receive either oxytocin intramuscularly or misoprostol rectally after spinal anesthesia.
Results: There was no significant difference between the two groups about change in postpartum hemoglobin, need for blood transfusion and incidence of PPH. We also did not observe any significant difference in any side effects.
Conclusions: Misoprostol may be considered as an alternative for oxytocin in low resource clinical settings.
References
Devine PC. Obstetric haemorrhage. Semin Perinatol. 2009;33:76-81.
Magann EF, Evans S, Hutchinson M, Collins R, Howard BC, Morrison JC. Postpartum haemorrhage after vaginal birth: an analysis of risk factors. South Med J. 2005;98:419-22.
Magann EF, Evans S, Hutchinson M, Collins R, Lanneau G, Morrison JC. Post-partum haemorrhage after cesarean delivery: an analysis of risk factors. South Med J. 2005;98:681-5.
Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk factors of severe obstetric haemorrhage. BJOG. 2008;115:1265-72.
Gant NF, Worley RJ. Measurement of uteroplacental blood flow in the human. In: Rosenfeld CR, Cox BE, Roy T, Ronald R, eds. The Uterine Circulation. Ithaca, NY: Perinatology Press; 1989: 53-73.
Rojers J, Wood J, McCandlish R, Ayers S, Trusdale A, Elbourne D. Active versus expectant management of third stage of labor: the Hinchinbrook randomised controlled trial. Lancet. 1998;39:693-9.
Khan Go, John Wanies, Doberty T, Sibai MB. Controlled cord traction versus minimal intervention techniques in delivery of placenta: a randomized controlled trial. Am J Obstet Gynaecol 1997;177:770-4.
Blanks AM, Thornton S. The role of oxytocin in parturition. BJOG. 2003;110(Suppl 20):46-51.
Chong YS, Su LL, Arulkumaran S. Misoprostol: a quarter century of use, abuse, and creative misuse. Obstet Gynaecol Surv. 2004;59(2):128-40.
Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB et al. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomized controlled trial. Lancet. 2006;368(9543):1248-53.
Gupta B, Jain V, Aggarwal N. Rectal misoprostol versus oxytocin in the prevention of postpartum haemorrhage: a pilot study. Int J Gynaecol Obstet. 2006;94(Suppl 2):S139-40.
Gerstenfeld TS, Wing DA. Rectal misoprostol versus intravenous oxytocin for the prevention of postpartum hemorrhage after vaginal delivery. Am J Obstet Gynaecol. 2001;185(4):878-82.
Nasr A, Shahin AY, Elsamman AM, Zakherah MS, Shaaban OM. Rectal misoprostol versus intravenous oxytocin for prevention of post-partum haemorrhage. Int J Gynaecol Obstet. 2009 Jun;105(3):244-7.
Shrestha A, Dongol A, Chawla CD, Adhikari RK. Rectal misoprostol versus intramuscular oxytocin for prevention of post-partum hemorrhage. Kathmandu Univ Med J (KUMJ). 2011 Jan-Mar;9(33):8-12.
Rajaei M, Karimi S, Shahboodaghi Z, Mahboobi H, Khorgoei T, Rajaei F. Safety and efficacy of misoprostol versus oxytocin for the prevention of postpartum haemorrhage. J Pregnancy. 2014;2014:713879.
Gohil JT, Tripathi B. A study to compare the efficacy of misoprostol, oxytocin, methyl-ergometrine and ergometrine-oxytocin in reducing blood loss in active management of 3rd stage of labor. J Obstet Gynaecol India. 2011 Aug;61(4):408-12.
Fazel MR, Mansoure-Samimi, Esmaeil-Fakharian A. Comparison of rectal misoprostol and intravenous oxytocin on hemorrhage and homeostatic changes during cesarean section. Middle East J Anaesthesiol. 2013;22(1):41-6.
Chaudhuri P, Banerjee GB, Mandal A. Rectally administered misoprostol versus intravenous oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss. Int J Gynaecol Obstet. 2010;109(1):25-9.
Vimala N, Mittal S, Kunar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynaecol Obstet. 2006;92(2):106-10.
Shojai R, Desbrière R, Dhifallah S, Courbière B, Ortega D, d'Ercole C et al. Rectal misoprostol for postpartum hemorrhage (in French). Gynaecol Obstet Fertil. 2004;32(9):703-7.
Baruah M, Cohn GM. Efficacy of rectal misoprostol as second-line therapy for the treatment of primary postpartum haemorrhage. J Reprod Med. 2008;53(3):203-6.
Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2007;(1):CD003249.
Bamigboye AA, Merrell DA, Hofmeyr GJ, Mitchell R. Randomized comparison of rectal misoprostol with Syntometrine for management of third stage of labor. Acta Obstet Gynaecol Scand. 1998;77(2):178-81.
Nellore V, Mittal S, Dadhwal V. Rectal misoprostol vs. 15-methyl prostaglandin F2 alpha for the prevention of postpartum haemorrhage. Int J Gynaecol Obstet. 2006;94(1):45-6.
